Results 161 to 170 of about 3,895,024 (310)

Military Operations Research Society (MORS) Oral History Project Interview of Dr. Susan M. Sanchez

Interviewers: W. David Kelton, Ms. Tammy McNeley, and Dr. Bob SheldonDr. Susan M. Sanchez is a Distinguished Professor Emerita in the Operations Research (OR) Department at the Naval Postgraduate School (NPS). She joined the OR Department at NPS in 2000.
Sanchez, Susan M.
core  

WS53: The Development of Brain Banks in the UK c.1970–c.2010 (12-Nov-2013)

, 2017
Selection of photos taken at the Witness Seminar “The Development of Brain Banks in the UK c.1970–c.2010” held by the History of Modern Biomedicine Research Group, 12-Nov-2013.

core  

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Military Operations Research Society (MORS) Oral History Project Mr. Franklin McKie

Interviewer: Dr. Bob SheldonFranklin McKie was an operations research analyst for the United States Army Center for Army Analysis (CAA) from 1973 to 2004, where his final role was Chief of the Mobilization and Deployment Division.
McKie, Franklin
core  

WS46: Clinical Cancer Genetics: Polyposis and Familial Colorectal Cancer c.1975-c.2010 (25-Sep-2012)

, 2017
Selection of photos taken at the Witness Seminar “Clinical Cancer Genetics: Polyposis and Familial Colorectal Cancer c.1975-c.2010” held by the History of Modern Biomedicine Research Group, 25-Sep-2012.

core  

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

‘US-Gallasch’: A New Citrus Rootstock 60 Years in the Making

HortScience
Malcolm W. Smith, Debra L. Gultzow, Toni K. Newman, Michael Reid, Robert R. Krueger, Mikeal L. Roose, Claire T. Federici, Kim D. Bowman   +7 more
doaj   +1 more source

WS48: Clinical Molecular Genetics in the UK c.1975–c.2000 (05-Feb-2013)

, 2017
Selection of photos taken at the Witness Seminar “Clinical Molecular Genetics in the UK c.1975–c.2000” held by the History of Modern Biomedicine Research Group, 05-Feb-2013.

core  

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

WS56: The Development of Waste Management in the UK c.1960–c.2000 (25-Feb-2014)

, 2017
election of photos taken at the Witness Seminar “The Development of Waste Management in the UK c.1960–c.2000" held by the History of Modern Biomedicine Research Group, 25-Feb-2014.

core